Galectin-3 levels and the prediction of atrial high-rate episodes in patients with cardiac resynchronization therapy

Aksan, Gökhan; Yanık, Ahmet; Yontar, Osman Can; Gedikli, Ömer; Arslan, Uğur; Soylu, Korhan

doi:10.1136/jim-2020-001459

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Aksan et al, CRT patients who had high galectin-3 levels were more likely to develop AHREs [12]. However, although Gal-3 was not identified as an independent predictor in our study's multivariate analysis, it was related with a higher risk of developing AHREs in the univariate analysis.…”

Section: Discussioncontrasting

confidence: 75%

Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers

Simu

Tomoaia

Roşu

et al. 2023

IJMS

View full text Add to dashboard Cite

Atrial high-rate episodes (AHREs) are atrial tachyarrhythmias that are exclusively detected by cardiac implantable electronic devices (CIEDs) with an atrial lead. The objective of this study was to investigate the incidence and predictive factors for AHREs, and to evaluate the ability of inflammation biomarkers to predict the occurrence of AHREs. 102 patients undergoing CIED procedure who received a dual chamber pacemaker were included. CIED interrogation was performed 1 year after the implantation procedure. Patients were divided into groups according to the occurrence of AHREs, which was the primary endpoint of the study. The mean age of the patients was of 73 ± 8.6 years and 48% were male. The incidence of AHREs was 67% at 1 year follow-up. Patients with AHREs were older, had higher left atrial indexed volume (LAVi), higher baseline galectin-3 levels (1007.5 ± 447.3 vs. 790 ± 411.7 pg/mL) and received betablockers more often, along with amiodarone and anticoagulants. Interestingly, the CHADSVASC score did not differ significantly between the two groups. A cut-off value of galectin > 990 pg/mL predicted AHREs with moderate accuracy (AUC of 0.63, 95% CI 0.52 to 0.73, p = 0.04), and this association was confirmed in the univariate regression analysis (OR 1.0012, 95% CI 1.0001 to 1.0023, p = 0.0328). However, based on the multivariate regression analysis, galectin lost its prognostic significance under the effect of LAVi, which remained the only independent predictor of AHREs (OR 1.0883, 95% CI 1.0351 to 1.1441, p = 0.0009). AHREs are common in CIEDs patients. Galectin-3 may bring additional data in the prediction of AHREs.

show abstract

Section: Discussioncontrasting

confidence: 75%

Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers

Simu

Tomoaia

Roşu

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Nonetheless, the study did not demonstrate that elevated Gal-3 serum concentration was associated with prevalent AF in the HF population. The opposite result was shown in the prospective study by Aksan et al in HF patients undergoing CRT [133]. The study revealed that Gal-3 serum concentration was significantly higher in patients with atrial high-rate (AHR) episodes, which were related to AF than in those without AHR episodes.…”

Section: Heart Failure With Atrial Fibrillationmentioning

confidence: 74%

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Zaborska,

Sikora-Frąc,

Smarż

et al. 2023

IJMS

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome with high morbidity and mortality, and its prevalence is rapidly increasing. Galectin-3 (Gal-3) is an important factor in the pathophysiology of HF, mainly due to its role in cardiac fibrosis, inflammation, and ventricular remodeling. Fibrosis is a hallmark of cardiac remodeling, HF, and atrial fibrillation development. This review aims to explore the involvement of Gal-3 in HF and its role in the pathogenesis and clinical diagnostic and prognostic significance. We report data on Gal-3 structure and molecular mechanisms of biological function crucial for HF development. Over the last decade, numerous studies have shown an association between echocardiographic and CMR biomarkers in HF and Gal-3 serum concentration. We discuss facts and concerns about Gal-3’s utility in acute and chronic HF with preserved and reduced ejection fraction for diagnosis, prognosis, and risk stratification. Finally, we present attempts to use Gal-3 as a therapeutic target in HF.

show abstract

The role of galectin-3 in atrial fibrillation

Procyk,

Czapla,

Jałocha

et al. 2023

J Mol Med

View full text Add to dashboard Cite

Numerous risk factors for atrial fibrillation (AF) progression have been identified. However, the biomarkers mentioned in the guidelines do not have any clinically relevant predictive value. Some research groups investigated the potential utility of galectin-3 (gal-3) as a diagnostic, prognostic, and predictive biomarker in AF. In this review, we have thoroughly summarized the current data on the role of gal-3 in AF based on the original research in this field. Patients suffering from AF present with increased levels of gal-3. The concentration of gal-3 differs between patients with AF depending on the type of AF — it is higher in patients with persistent AF than in patients with paroxysmal AF. Multiple studies investigating the reappearance of AF in patients who underwent ablation have shown that gal-3 is a promising biomarker to predict the outcome of this therapy. Patients with increased levels of gal-3 are at higher risk of AF recurrence. Although the research considered in this work addressed many aspects of the role of gal-3 in AF, most of it has been conducted on a small group of patients. Therefore, further research and extensive clinical trials confirming described findings are highly warranted.

show abstract

Galectin-3 levels and the prediction of atrial high-rate episodes in patients with cardiac resynchronization therapy

Cited by 3 publications

References 46 publications

Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers

Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

The role of galectin-3 in atrial fibrillation

Contact Info

Product

Resources

About